Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2022-10-28 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2022年第三季度报告提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (477 characters) indicating that the company's 2022 third quarter report has been approved and is available on the official disclosure website. It does not contain the actual financial data or the full report itself, but rather directs investors to where the full report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the full Interim/Quarterly Report (IR).
2022-10-28 Chinese
关于止咳橘红颗粒获得临床试验许可的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (838 characters) from a pharmaceutical company about obtaining clinical trial permission for a product. It contains no financial data, no detailed financial performance, no management discussion, no voting results, no regulatory certifications, and no mention of report attachments. It is an official company announcement about a regulatory approval related to product development. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-09-26 Chinese
关于公司原出售广东康芝医院管理有限公司100%股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a previously disclosed transaction involving the sale of 100% equity in Guangdong Kangzhi Hospital Management Co., Ltd. It details receipt of payment installments and completion of related procedures. The document is short (1232 characters) and focuses on updating shareholders about the transaction status rather than providing full financial statements or detailed financial analysis. It does not contain financial results, audit opinions, or management discussions. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-09-08 Chinese
关于参加海南辖区投资者网上集体接待日暨上市公司业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor meeting and performance explanation session organized by regulatory and industry bodies. It mentions discussing the 2021 annual report and 2022 interim report but does not contain any actual financial data or detailed report content. The document is short (616 characters) and serves as a notice of an upcoming event rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about investor communication and not the actual annual or interim report.
2022-09-08 Chinese
独立董事关于第五届董事会第二十七次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's 2022 semi-annual report and related issues such as external guarantees, related party transactions, and use of raised funds. It references the 2022 half-year period (January 1 to June 30, 2022) and discusses compliance with regulatory requirements and internal procedures. The document is not the semi-annual report itself but an independent opinion on the report and related matters, which is typical for audit or independent directors' opinions accompanying interim reports. The document length is 2178 characters, which is relatively short and focused on independent opinions rather than full financial statements or detailed analysis. Therefore, it fits best under Audit Report / Information (AR), as it provides audit-related independent opinions on the interim report and related compliance issues, rather than being the interim report itself (IR) or a regulatory announcement (RNS). H1 2022
2022-08-22 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022 半年度报告摘要" which translates to "2022 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. It also includes notes on audit opinions, shareholder structure, and important events during the reporting period. The length is about 4051 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary notice. The content matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-22 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.